Friday November 27 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioPortfolio's Approved Drugs Database

Baraclude

Entecavir

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Press Releases About Baraclude:

 BioPortfolio Logo
Bristol-Myers Squibb Welcomes NICE Guidance Recommending Baraclude(R) (entecavir) as a Treatment Option for Chronic Hepatitis B 29th August, 2008
UXBRIDGE, England, August 29 /PRNewswire/ -- NICE (National Institute for Health and Clinical Excellence) has published guidance that recommends Baraclude(R) (entecavir) as an option for treatment of
China's Hepatitis B Virus Drug Market Will Grow to $800 Million by 2012 28th August, 2008 Decision Resources
WALTHAM, Mass., Aug. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the Chinese
Chronic viral hepatitis: B is for billions 1st March, 2005 Datamonitor
Chronic viral hepatitis: B is for billions Despite recent advances in the treatment and management of hepatitis B, the market is still relatively immature, with several key unmet needs.

This page has been viewed 23 times Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Baraclude across BioPortfolio, or for Baraclude Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.